Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Lymphangioleiomyomatosis (LAM)
NCT02116712Phase 1Completed
- Start
- Aug 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of saracatinib in lymphangioleiomyomatosis (LAM). Primary endpoint: Dose Determination at 8 weeks. Started Aug 2014; status: completed.
02
Drugs
saracatinib
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT02116712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116712.